Adam D Cohen, MD
Associate Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania
Director, Myeloma Immunotherapy, University of Pennsylvania
Member, Abramson Cancer Center
Co-Director, Amyloidosis Program, University of Pennsylvania
Department: Medicine
Contact information
Perelman Center for Advanced Medicine
12th Floor, South Pavilion
Office #12-175
3400 Civic Center Blvd
Philadelphia, PA 19104
12th Floor, South Pavilion
Office #12-175
3400 Civic Center Blvd
Philadelphia, PA 19104
Office: 215-615-5853
Fax: 215-615-5887
Fax: 215-615-5887
Education:
BA
Harvard University, 1994.
MD
University of Pennsylvania, 1999.
Permanent linkBA
Harvard University, 1994.
MD
University of Pennsylvania, 1999.
Description of Clinical Expertise
Multiple MyelomaAmyloidosis
POEMS syndrome
Monoclonal gammopathies
Waldenstrom's Macroglobulinemia
Description of Research Expertise
Cancer immunotherapyCellular therapy
Phase I trials
CAR T cells
Selected Publications
Ho M, Paruzzo L, Noll JH, Stella F, Devi P, Ndeupen S, Chen GM, Cohen IJ, Ramirez-Fernandez A, Waxman A, Kapur S, Chen F, Xu R, Huff A, Jarocha D, Patel V, Bochi-Layec AC, Ramasubramanian R, Liu S, Bouvier R, De Souza VB, Petal H, Li Z, Carturan A, Michener P, Hopkins CR, Koucky O, Minehart J, Dimitri A, Nabar NR, Hasanali ZS, Ciccarelli B, Willians E, Bartoszek R, Lavorando M, Suyash M, Gonzalez VE, Porazzi P, Bhoj V, Apostolidis SA, Vogl DT, Porter DL, Scholler J, Diorio C, Roche AM, Everett JK, Bushman FD, Nathanson KL, Stadtmauer EA, Susanibar-Adaniya SP, Garfall AL, Ruella M*, Cohen AD*, Fraietta JA*. : CD4⁺ T-cells mediate ‘CART-associated Immune-Related Adverse Events’ (CirAE) after BCMA CAR T Therapy. Nature Medicine 2025 Notes: accepted for publication *co-senior authors.Yu KL, Ho M, Paruzzo L, Stella F, Patel H, Hasanali Z, Kapur S, Waxman AJ, Vogl DT, Stadtmauer EA, Fraietta JA, Ruella M, Cohen AD, Garfall AL, Susanibar-Adaniya S: Outcomes of relapse after teclistamab therapy in multiple myeloma. Blood Cancer Journal 2025 Notes: accepted for publication.
Musa H, Mielnik M, Trudel S, Weisel K, Mockus-Daehn T, Ferron-Brady G, Hong Q, Ma Y, Pater S, Suchindran S, Zhou X, Richardson PG, Cohen AD*, Lowther DE*: No evidence of B-cell maturation antigen loss or systemic immune impairment following belantamab mafodotin treatment in multiple myeloma. Haematologica 2025 Notes: 2025 Aug 28. doi: 10.3324/haematol.2025.288203. Online ahead of print *co-senior authors.
Jagannath S, Martin TG, Lin Y, Cohen AD, Raje N, Htut M, Deol A, Agha M, Berdeja JG, Lesokhin AM, Liegel JJ, Rossi A, Lieberman-Cribbin A, Usmani SZ, Dhakal B, Parekh S, Li H, Wang F, Montes de Oca R, Plaks V, Sun H, Banerjee A, Schecter JM, Lendvai N, Madduri D, Lengil T, Zhu J, Koneru M, Akram M, Patel N, Costa Filho O, Jakubowiak AJ, Voorhees PM: Long-Term (5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma. Journal of Clinical Oncology 43: 2766-71, 2025.
Ho M, Paruzzo L, Minehart J, Voruganti T, Devi P, Vogl DT, Cohen AD, Garfall AL, Waxman AJ, Kapur S, Stadtmauer EA, Adaniya SS, Longworth S: Non-tuberculous mycobacterial infections following teclistamab in multiple myeloma. Haematologica 110: 1436-42, June 2025.
98. Jadlowsky JK, Hexner EO, Marshall A, Grupp SA, Frey NV, Riley JL, Veloso E, McConville H, Rogal W, Czuczman C, Hwang WT, Li Y, Leskowitz RM, Farrelly O, Karar J, Christensen S, Barber-Rotenberg J, Gaymon A, Aronson N, Bernstein W, Melenhorst JJ, Roche AM, Everett JK, Zolnoski SA, McFarland AG, Reddy S, Petrichenko A, Cook EJ, Lee C, Gonzalez VE, Alexander K, Kulikovskaya I, Ramírez-Fernández Á, Minehart JC, Ruella M, Gill SI, Schuster SJ, Cohen AD, Garfall AL, Shah PD, Porter DL, Maude SL, Levine BL, Siegel DL, Chew A, McKenna S, Lledo L, Davis MM, Plesa G, Herbst F, Stadtmauer EA, Tebas P, DiNofia A, Haas A, Haas NB, Myers R, O'Rourke DM, Svoboda J, Tanyi JL, Aplenc R, Jacobson JM, Ko AH, Cohen RB, June CH, Bushman FD, Fraietta JA: Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies. Nature Medicine 31: 1134-1144, Apr 2025.
Chen GM, Gering D, Satulovsky J, Datta S, Lai P, Karar J, Gonzalez VE, Alexander K, Chew A, Jadlowsky JK, Moody, Carolan E, Ruella M, Paruzzo L, Amses KR, Stadtmauer EA, Frey NV, Hexner EO, Porter DL, Cohen AD, Gill SI, Garfall AL, Schuster SJ, Mo K, Liang SI, Spasic M, Levine BL, Siegel DL, Ramirez-Fernandez A, Mackall CL, Bushman FD, Good Z, Wherry EJ, June CH, Fraietta JA: Predictive biomarkers of response to chimeric antigen receptor (CAR) T-cell therapy for pan-hematologic cancer. Nature Biomedical Engineering 2025 Notes: accepted for publication.
Stalker M, Garfall A, Cohen AD, Vogl DT, Djulbegovic M, Susanibar-Adaniya S, Stadtmauer E, Megherea O, Waxman AJ: Safety and efficacy of teclistamab in patients with relapsed or refractory AL amyloidosis: a retrospective case series. European Journal of Haematology 114: 443-447, Mar 2025.
Costa LJ, Banerjee R, Mian H, Weisel KC, Bal S, Derman BA, Htut MM, Nagarajan C, Rodriguez C, Richter J, Frigault MJ, Ye JC, van de Donk NWCJ, Voorhees PM, Puliafito B, Bahlis N, Popat R, Chng WJ, Ho PJ, Kaur G, Kapoor P, Du J, Schjesvold F, Berdeja J, Einsele H, Cohen AD, Mikhael J, Biru Y, Rajkumar SV, Lin Y, Martin TG, Chari A: International Myeloma Working Group Immunotherapy Committee Recommendation on Sequencing Immunotherapy for Treatment of Multiple Myeloma. Leukemia 39: 543-554, Mar 2025.
Hasanali ZS, Razzo B, Susanibar-Adaniya SP, Garfall AL, Stadtmauer EA, Cohen AD: CAR T cells in the treatment of Multiple Myeloma. Hematology/Oncology Clinics 2024.
Elghawy O, Deshpande S, Sussman J, Garfall A, Cohen A, Kapur S, Susanibar-Adaniya S, Vogl D, Waxman A, Stadtmauer E: Characteristics and outcomes of therapy-related acute leukemia following autologous transplant (auto-HCT) for multiple myeloma. Bone Marrow Transplantation 60(1): 64-68, Jan 2025.
Gaballa MR, Puglianini OC, Cohen A, Vogl D, Chung A, Ferreri CJ, Voorhees P, Hansen DK, Patel KK: BCMA-directed CAR T-cell therapy in patients with multiple myeloma and CNS involvement. Blood Advances 9: 1171-1180, Mar 2025.